Clear Street initiated coverage of Rapt Therapeutics (RAPT) with a Buy rating and $3 price target
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPT:
- RAPT Therapeutics Faces Nasdaq Delisting Notice
- Rapt Therapeutics price target lowered to $1 from $2 at UBS
- Rapt Therapeutics assumed with a Buy at H.C. Wainwright
- RAPT Therapeutics: Promising Clinical Developments and Strong Financial Performance Justify Buy Rating
- RAPT Therapeutics Reports Improved Q1 2025 Results